In the clinical trials of new MS medications and procedures, why has the participation of racial and ethnic minority individuals been so low? Is it a difficulty with outreach? Are the patient barriers to participation underrecognized and underaddressed? Does historical mistrust of the medical community remain a strong negative? What should clinicians and trial designers do to increase diversity to improve care for all individuals with MS?

Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/223/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/221)

Hosted on Acast. See acast.com/privacy for more information.

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.

Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/222/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/218)

Hosted on Acast. See acast.com/privacy for more information.

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.

Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/219/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/216)

Hosted on Acast. See acast.com/privacy for more information.